Physician profile
Nuha Mulk
NPI 1629539150
$983.94
in general payments reported to CMS, 2019-2025
14 companies · $24.77 in 2025
The $24.77 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.64 · 2023: $344 · 2024: $530 · 2025: $24.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $228.68 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $129.60 | 2023-2024 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $113.54 | 2022-2024 | Repatha, Krystexxa, Evenity |
| Philips North America LLC | $78.09 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.41 | 2022-2024 | Synjardy, Jardiance, Tradjenta |
| Abbvie INC. | $71.19 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $70.21 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $64.93 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $43.82 | 2023-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $24.90 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $24.77 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $24.24 | 2024 | Voquezna |
| Opko Pharmaceuticals, LLC | $17.96 | 2022 | |
| Mylan Specialty L.P. | $16.60 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nuha Mulk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.